Alnylam Pharmaceuticals Balance Sheet Health
Financial Health criteria checks 5/6
Alnylam Pharmaceuticals has a total shareholder equity of $32.4M and total debt of $2.4B, which brings its debt-to-equity ratio to 7566.4%. Its total assets and total liabilities are $4.2B and $4.2B respectively.
Key information
7,566.4%
Debt to equity ratio
US$2.45b
Debt
| Interest coverage ratio | n/a |
| Cash | US$2.78b |
| Equity | US$32.35m |
| Total liabilities | US$4.17b |
| Total assets | US$4.21b |
Recent financial health updates
No updates
Recent updates
Financial Position Analysis
Short Term Liabilities: A1LN34's short term assets ($3.4B) exceed its short term liabilities ($1.2B).
Long Term Liabilities: A1LN34's short term assets ($3.4B) exceed its long term liabilities ($3.0B).
Debt to Equity History and Analysis
Debt Level: A1LN34 has more cash than its total debt.
Reducing Debt: A1LN34's debt to equity ratio has increased from 0% to 7566.4% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: Whilst unprofitable A1LN34 has sufficient cash runway for more than 3 years if it maintains its current positive free cash flow level.
Forecast Cash Runway: A1LN34 is unprofitable but has sufficient cash runway for more than 3 years, due to free cash flow being positive and growing by 19.9% per year.